# Axcelis Technologies Inc: Form 10-Q for the period ended Sep 30, 2019

- Company: [Axcelis Technologies Inc](/companies/acls.md) (CIK 1113232)
- Form: 10-Q
- Filed: 2019-11-07
- Accepted by EDGAR: Nov 7, 2019, 10:50 ET
- Period: 2019-09-30
- Accession: 0001558370-19-010306
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1113232/000155837019010306/acls-20190930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1113232/000155837019010306/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $69.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $235.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $38.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $135.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $30.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $99.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $12.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $40.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $1.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | $11.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $1.3m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $3.8m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | −$328.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $943.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $704.0k | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | $7.3m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | $0.22 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 33,323,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 33,821,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | −$345.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $11.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2019-01-01 to 2019-09-30 | $14.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-09-30 | $155.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $353.9m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $530.5m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $63.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $122.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | $407.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 29,043 characters.

*Certain statements within "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements that involve risks and uncertainties. Words such as may, will, should, would, anticipates, expects, intends, plans, believes, seeks, estimates and similar expressions identify such forward-looking statements. The forward-looking statements contained herein are based on current expectations and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Factors that might cause such a difference include, among other things, those set forth under "Liquidity and Capital Resources" below and under “Risk Factors” in Part II, Item 1A to our annual report on Form 10-K for the year ended December 31, 2018*, which discussion is incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. We assume no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting forward-looking statements, except as may be required by law.

### Overview

We are primarily a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe and Asia. In addition, we provide extensive worldwide aftermarket service and support, including spare parts, equipment upgrades and maintenance services to the semiconductor industry. Our product development and manufacturing activities occur primarily in the United States. Our equipment and service products are highly technical and are sold primarily through a direct sales force in the United States, Europe and Asia. Consolidation and partnering within the semiconductor manufacturing industry has resulted in a small number of customers representing a substantial portion of our business. Our ten largest customers accounted for 76.2% of total revenue for the nine months ended September 30, 2019.

In the first nine months of 2019, our revenues were adversely affected by the current industry slowdown, but we maintained profitability at the lower revenue level, resulting from both improved gross margin and expense control. We have taken steps to reduce operating expenses through a variety of programs while continuing to make the necessary investments in the business required to drive growth. Our strong gross margins in the third quarter are due to cost-out initiatives and favorable product mix.

### Critical Accounting Estimates

Management’s discussion and analysis of our financial condition and results of operations included herein and in our Annual Report on Form 10-K for the year ended December 31, 2018 are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and assumptions. Management’s estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Management has not identified any need to make any material change in, and has not changed, any of our critical accounting estimates and judgments as described in Management’s Discussion and Analysis of Financial Conditions and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2018.

### Results of Operations

The following table sets forth our results of operations as a percentage of total revenue:

| Revenue: | Three months ended September 30, 2019 | 2018 | Nine months ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Product | 92.6% | 92.8% | 92.3% | 94.1% |
| Services | 7.4 | 7.2 | 7.7 | 5.9 |
| Total revenue | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of revenue: |  |  |  |  |
| Product | 48.4 | 51.6 | 50.2 | 53.9 |
| Services | 7.6 | 6.6 | 7.4 | 5.8 |
| Total cost of revenue | 56.0 | 58.2 | 57.6 | 59.7 |
| Gross profit | 44.0 | 41.8 | 42.4 | 40.3 |
| Operating expenses: |  |  |  |  |
| Research and development | 18.6 | 13.5 | 17.1 | 11.2 |
| Sales and marketing | 11.6 | 8.3 | 10.8 | 7.5 |
| General and administrative | 11.1 | 8.9 | 9.8 | 7.3 |
| Total operating expenses | 41.3 | 30.7 | 37.7 | 26.0 |
| Income from operations | 2.7 | 11.1 | 4.7 | 14.3 |
| Other (expense) income: |  |  |  |  |
| Interest income | 1.0 | 0.6 | 1.0 | 0.5 |
| Interest expense | (1.9) | (1.4) | (1.6) | (1.1) |
| Other, net | (1.3) | (0.6) | (0.5) | (0.5) |
| Total other expense | (2.2) | (1.4) | (1.1) | (1.1) |
| Income before income taxes | 0.5 | 9.7 | 3.6 | 13.2 |
| Income tax (benefit) provision | (0.5) | 0.5 | 0.4 | 2.1 |
| Net income | 1.0% | 9.2% | 3.2% | 11.1% |

### Revenue

The following table sets forth our revenue:

*(dollars in thousands)*

| Revenue: | Three months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Product | $64,290 | $88,496 | $(24,206) | (27.4)% | $217,201 | $317,039 | $(99,838) | (31.5)% |
| Percentage of revenue | 92.6% | 92.8% |  |  | 92.3% | 94.1% |  |  |
| Services | 5,163 | 6,878 | (1,715) | (24.9)% | 18,034 | 19,853 | (1,819) | (9.2)% |
| Percentage of revenue | 7.4% | 7.2% |  |  | 7.7% | 5.9% |  |  |
| Total revenue | $69,453 | $95,374 | $(25,921) | (27.2)% | $235,235 | $336,892 | $(101,657) | (30.2)% |

#### Three months ended September 30, 2019 Compared with Three months ended September 30, 2018

#### Product

Product revenue, which includes systems sales, sales of spare parts, product upgrades and used systems was $64.3 million, or 92.6% of revenue during the three months ended September 30, 2019, compared with $88.5 million, or

92.8% of revenue for the three months ended September 30, 2018. The $24.2 million decrease in product revenue for the three month period ending September 30, 2019, in comparison to the same period in 2018, was primarily driven by a decrease in the number of systems sold.

A portion of our revenue from systems sales is deferred until installation and other services related to future performance obligations are performed. The total amount of deferred revenue at September 30, 2019 and December 31, 2018 was $27.4 million and $22.6 million, respectively. The net increase in deferred revenue is primarily due to the timing of system acceptances.

#### Services

Services revenue, which includes the labor component of maintenance and service contracts and fees for service hours provided by on-site service personnel, was $5.2 million, or 7.4% of revenue for the three months ended September 30, 2019, compared with $6.9 million, or 7.2% of revenue for the three months ended September 30, 2018. Although services revenue typically increases with the expansion of the installed base of systems, it can fluctuate from period to period based on capacity utilization at customers’ manufacturing facilities, which affects the need for equipment service.

#### Nine months ended September 30, 2019 Compared with Nine months ended September 30, 2018

#### Product

Product revenue, which includes systems sales, sales of spare parts, product upgrades and used systems was $217.2 million, or 92.3% of revenue during the nine months ended September 30, 2019, compared with $317.0 million, or 94.1% of revenue for the nine months ended September 30, 2018. The $99.8 million decrease in product revenue for the nine month period ending September 30, 2019, in comparison to the same period in 2018, was primarily driven by a decrease in the number of systems sold.

#### Services

Services revenue was $18.0 million, or 7.7% of revenue for the nine months ended September 30, 2019, compared with $19.9 million, or 5.9% of revenue for the nine months ended September 30, 2018.

### Revenue Categories used by Management

In addition to the line item revenue categories discussed above, management also regularly disaggregates revenue in the following categories, which it finds relevant and useful:

- Ion implant revenue separate from revenue from legacy non-implant product lines, given that ion implantation systems are the primary driver of our growth and strategic objectives;
- Systems and Aftermarket revenues, in which “Aftermarket” is

A. the portion of Product revenue relating to spare parts, product upgrades and used systems combined with

B. Services revenue, which is the labor component of aftermarket revenues;

Aftermarket purchases reflect current fab utilization as opposed to Systems purchases which reflect capital investment decisions by our customers, which have differing economic drivers;

- Revenue by geographic regions, since economic factors impacting customer purchasing decisions may vary by geographic region; and
- Revenue by our customer market segments, since they can be subject to different economic drivers at different periods of time, impacting a customer’s likelihood of purchasing capital equipment during any particular period. Currently, management references three customer market segments: memory, mature

technology processes and leading edge foundry and logic.

The ion implant and Aftermarket revenue categories for recent periods are discussed below.

#### Three months ended September 30, 2019 Compared with Three months ended September 30, 2018

#### Ion Implant

Included in total revenue of $69.5 million during the three months ended September 30, 2019 is revenue from sales of ion implant of $65.2 million, or 93.9% of total revenue, compared with $90.4 million, or 94.8%, of total revenue for the three months ended September 30, 2018. The remaining $4.3 million of revenue for the three months ended September 30, 2019 was non-ion implant services.

#### Aftermarket

Included in total revenue of $69.5 million during the three months ended September 30, 2019 is revenue from our Aftermarket business of $32.6 million, compared to $39.0 million for the three months ended September 30, 2018. The remaining $36.8 million of revenue for the three months ended September 30, 2019 was from system sales. Aftermarket revenue fluctuates from period to period based on capacity utilization at customers’ manufacturing facilities, which affects the sale of spare parts and demand for equipment service. Aftermarket revenue can also fluctuate from period to period based on the demand for system upgrades or used tools.

#### Nine months ended September 30, 2019 Compared with Nine months ended September 30, 2018

#### Ion Implant

Included in total revenue of $235.2 million during the nine months ended September 30, 2019 is revenue from sales of ion implant of $222.4 million, or 94.5% of total revenue, compared with $320.8 million, or 95.2%, of total revenue for the nine months ended September 30, 2018. The remaining $12.8 million of revenue for the nine months ended September 30, 2019 was non-ion implant services.

#### Aftermarket

Included in total revenue of $235.2 million during the nine months ended September 30, 2019 is revenue from our Aftermarket business of $104.1 million, compared to $121.1 million for the nine months ended September 30, 2018. The remaining $131.1 million of revenue for the nine months ended September 30, 2019 was from system sales.

### Gross Profit / Gross Margin

The following table sets forth our gross profit / gross margin:

*(dollars in thousands)*

| Gross Profit: | Three months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Product | $30,703 | $39,360 | $(8,657) | (22.0)% | $99,096 | $135,616 | $(36,520) | (26.9)% |
| Product gross margin | 47.8% | 44.5% |  |  | 45.6% | 42.8% |  |  |
| Services | (122) | 553 | (675) | 122.1% | 740 | 453 | 287 | (63.4)% |
| Services gross margin | (2.4)% | 8.0% |  |  | 4.1% | 2.3% |  |  |
| Total gross profit | $30,581 | $39,913 | $(9,332) | (23.4)% | $99,836 | $136,069 | $(36,233) | (26.6)% |
| Gross margin | 44.0% | 41.8% |  |  | 42.4% | 40.3% |  |  |

22

#### Three months ended September 30, 2019 Compared with Three months ended September 30, 2018

#### Product

Gross margin from product revenue was 47.8% for the three months ended September 30, 2019, compared to 44.5% for the three months ended September 30, 2018. The increase in gross margin resulted from improved margins on Purion systems due to cost-out initiatives and favorable product mix.

#### Services

Gross margin from services revenue was (2.4)% for the three months ended September 30, 2019, compared to 8.0% for the three months ended September 30, 2018. The decrease in gross margin is attributable to changes in the mix of service contracts.

#### Nine months ended September 30, 2019 Compared with Nine months ended September 30, 2018

#### Product

Gross margin from product revenue was 45.6% for the nine months ended September 30, 2019, compared to 42.8% for the nine months ended September 30, 2018. The increase in gross margin resulted from improved margins on Purion systems.

#### Services

Gross margin from services revenue was 4.1% for the nine months ended September 30, 2019, compared to 2.3% for the nine months ended September 30, 2018. The increase in gross margin is attributable to changes in the mix of service contracts.

### Operating Expenses

The following table sets forth our operating expenses:

*(dollars in thousands)*

|  | Three months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $12,930 | $12,845 | $85 | 0.7% | $40,335 | $37,631 | $2,704 | 7.2% |
| Percentage of revenue | 18.6% | 13.5% |  |  | 17.1% | 11.2% |  |  |
| Sales and marketing | 8,057 | 7,923 | 134 | 1.7% | 25,411 | 25,246 | 165 | 0.7% |
| Percentage of revenue | 11.6% | 8.3% |  |  | 10.8% | 7.5% |  |  |
| General and administrative | 7,707 | 8,477 | (770) | (9.1)% | 23,097 | 24,755 | (1,658) | (6.7)% |
| Percentage of revenue | 11.1% | 8.9% |  |  | 9.8% | 7.3% |  |  |
| Total operating expenses | $28,694 | $29,245 | $(551) | (1.9)% | $88,843 | $87,632 | $1,211 | 1.4% |
| Percentage of revenue | 41.3% | 30.7% |  |  | 37.7% | 26.0% |  |  |

Our operating expenses consist primarily of personnel costs, including salaries, commissions, expected incentive plan payouts, stock-based compensation and related benefits and taxes; project material costs related to the design and development of new products and enhancement of existing products; and professional fees, travel and depreciation expenses.

Personnel costs are our largest expense, representing $16.9 million or 58.5% of our total operating expenses for the three month period ended September 30, 2019, compared to $18.1 million or 61.8% of our total operating expenses for the three month period ended September 30, 2018. Personnel costs were $52.6 million or 59.0% of our total operating expenses for the nine month period ended September 30, 2019, compared to $54.7 million or 62.5% of our total operating expenses for the nine month period ended September 30, 2018. The lower personnel costs for the three and nine month periods ended September 30, 2019 are primarily due to lower incentive based pay expense.

### Research and Development

*(dollars in thousands)*

|  | Three months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $12,930 | $12,845 | $85 | 0.7% | $40,335 | $37,631 | $2,704 | 7.2% |
| Percentage of revenue | 18.6% | 13.5% |  |  | 17.1% | 11.2% |  |  |

Our ability to remain competitive depends largely on continuously developing innovative technology, with new and enhanced features and systems and introducing them at competitive prices on a timely basis. Accordingly, based on our strategic plan, we establish annual R&D budgets to fund programs that we expect will solve customers’ high value, high impact, ion implantation challenges.

#### Three months ended September 30, 2019 Compared with Three months ended September 30, 2018

Research and development expense was $12.9 million during the three months ended September 30, 2019, an increase of $0.1 million, or 0.7%, relatively flat when compared to the three months ended September 30, 2018.

#### Nine months ended September 30, 2019 Compared with Nine months ended September 30, 2018

Research and development expense was $40.3 million during the nine months ended September 30, 2019, a $2.7 million, or 7.2%, increase from $37.6 million during the nine months ended September 30, 2018. The increase is primarily due to increased outside services and project materials cost to support the development of new products and enhancements of existing products.

### Sales and Marketing

*(dollars in thousands)*

|  | Three months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales and marketing | $8,057 | $7,923 | $134 | 1.7% | $25,411 | $25,246 | $165 | 0.7% |
| Percentage of revenue | 11.6% | 8.3% |  |  | 10.8% | 7.5% |  |  |

Our sales and marketing expenses result primarily from the sale of our equipment and services through our direct sales force. Moving forward, we will incur expenses associated with implementing the agreement with Screen Semiconductor Solutions Co. Ltd., to distribute Purion products to customers in Japan.

#### Three months ended September 30, 2019 Compared with Three months ended September 30, 2018

Sales and marketing expense was $8.1 million during the three months ended September 30, 2019, an increase of $0.1 million, or 1.7%, relatively flat when compared with $7.9 million during the three months ended September 30, 2018.

#### Nine months ended September 30, 2019 Compared with Nine months ended September 30, 2018

Sales and marketing expense was $25.4 million during the nine months ended September 30, 2019, an increase of $0.2 million, or 0.7%, relatively flat when compared with $25.2 million during the nine months ended September 30, 2018.

### General and Administrative

*(dollars in thousands)*

|  | Three months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| General and administrative | $7,707 | $8,477 | $(770) | (9.1)% | $23,097 | $24,755 | $(1,658) | (6.7)% |
| Percentage of revenue | 11.1% | 8.9% |  |  | 9.8% | 7.3% |  |  |

Our general and administrative expenses result primarily from the costs associated with our executive, finance, information technology, legal and human resource functions.

#### Three months ended September 30, 2019 Compared with Three months ended September 30, 2018

General and administrative expense was $7.7 million during the three months ended September 30, 2019, a decrease of $0.8 million, or 9.1%, compared with $8.5 million during the three months ended September 30, 2018. The decrease is primarily due to a decrease in incentive based pay expense.

#### Nine months ended September 30, 2019 Compared with Nine months ended September 30, 2018

General and administrative expense was $23.1 million during the nine months ended September 30, 2019, a decrease of $1.7 million, or 6.7%, compared with $24.8 million during the nine months ended September 30, 2018. The decrease is primarily due to a decrease in incentive based pay expense.

### Other (Expense) Income

*(dollars in thousands)*

|  | Three months ended September 30, 2019 | 2018 | Period-to-period change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-period change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Other expense | $(1,511) | $(1,322) | $(189) | (14.3)% | $(2,728) | $(3,979) | $1,251 | 31.4% |
| Percentage of revenue | (2.2)% | (1.4)% |  |  | (1.1)% | (1.1)% |  |  |

Other (expense) income consists primarily of interest relating to the finance lease obligation we incurred in connection with the 2015 sale of our headquarters facility and other financing obligations, foreign exchange gains and losses attributable to fluctuations of the US dollar against local currencies of certain of the countries in which we operate as well as interest earned on our invested cash balances.

Other expense was $1.5 million for the three months ended September 30, 2019, compared with $1.3 million for the three months ended September 30, 2018. The increase in other expense for the three month period ended September 30, 2019 compared to the three month period ended September 30, 2018, was primarily due to higher foreign currency exchange losses in the current year period compared to the prior year. Other expense was $2.7 million for the nine months ended September 30, 2019, compared with $4.0 million for the nine months ended September 30, 2018. The decrease in other expense for the nine month period ended September 30, 2019 compared to the nine month period ended September 30, 2018, was primarily due to lower foreign currency exchange losses in the current year and increased interest earned on our invested cash balances compared to the same period last year.

During the three and nine month periods ended September 30, 2019, we had no significant off-balance-sheet risk such as exchange contracts, option contracts or other hedging arrangements. During the three and nine month periods ended September 30, 2018, with the exception of operating lease agreements entered into by us, we had no significant off-balance-sheet risk such as exchange contracts, option contracts or other hedging arrangements.

### Income Tax (Benefit) Provision

*(dollars in thousands)*

|  | Three months ended September 30, 2019 | 2018 | Period-to-period change $% |  | Nine months ended September 30, 2019 | 2018 | Period-to-period change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Income tax (benefit) provision | $(328) | $508 | $(836) | (164.6)% | $943 | $7,036 | $(6,093) | 86.6% |
| Percentage of revenue | (0.5)% | 0.5% |  |  | 0.4% | 2.1% |  |  |

The income tax benefit was $0.3 million for the three months ended September 30, 2019, a decrease of $0.8 million when compared to the three months ended September 30, 2018. The $0.8 million decrease was primarily due to a decrease in pretax income for the period of $9.0 million as well as a $1.4 million tax benefit in the three months ended September 30, 2018, relating to the 2017 Tax Cut and Jobs Act.

The income tax provision was $0.9 million during the nine months ended September 30, 2019, a decrease of $6.1 million when compared to the nine months ended September 30, 2018. This change was primarily attributable to the decrease in pretax income of $36.2 million.

At December 31, 2018, we had $71.9 million of deferred tax assets worldwide comprised of net operating loss carryforwards, tax credit carryforwards and other temporary differences, which are available to reduce income tax liabilities in future years. This amount was net of a $6.8 million valuation allowance. As of September 30, 2019, the valuation allowance increased to $7.7 million due to the uncertainty of the utilization of certain research and development credits. Management considered the weight of all available evidence in determining whether a valuation allowance was required. After consideration of both positive and negative evidence, management concluded that it is more likely than not that a substantial portion of the Company’s deferred tax assets will be realized. The positive evidence considered was three year U.S. historical cumulative pretax income, projected future taxable income and length of carry-forward periods of net operating losses and tax credits. The primary negative evidence considered was the volatility of the semiconductor industry in which we operate.

### Liquidity and Capital Resources

We had $155.3 million in unrestricted cash and cash equivalents at September 30, 2019, in addition to $6.9 million in restricted cash, primarily comprised of the $5.9 million security for the lease of our corporate headquarters. Management believes that maintaining a strong cash balance is necessary to provide funding for potential ramps in our business which can require significant cash investment to meet sudden demand. Additionally, we are considering both organic and inorganic opportunities to drive future growth, for which cash resources will be necessary.

Our liquidity is affected by many factors. Some of these relate specifically to the operations of our business, for example, the rate of sale of our products, and others relate to the uncertainties of global economic conditions, including the availability of credit and the condition of the overall semiconductor equipment industry. Our established cost structure, other than cost of goods sold, does not vary significantly with changes in volume. We experience fluctuations in operating results and cash flows depending on these factors. We are also engaging in stock repurchases, as discussed below.

During the nine months ended September 30, 2019, we used $0.3 million of cash related to operating activities. In comparison, during the nine months ended September 30, 2018, we generated $17.2 million of cash from operations.

Investing activities for the nine months ended September 30, 2019 and 2018 resulted in cash outflows of $11.1 million and $3.9 million, respectively, used for capital expenditures. During the nine months ended September 30, 2019, we purchased machinery and equipment to support manufacturing and engineering operations.

Financing activities for the nine months ended September 30, 2019 used net cash of $12.2 million, $14.0 million of which related to the repurchase of our common stock and $1.6 million related to the payments made to government tax authorities for income tax withholding on RSU vesting, where shares are withheld by the Company. These amounts were partially offset by $3.4 million of proceeds related to the exercise of stock options and purchase of shares under our ESPP. Financing activities for the nine months ended September 30, 2018 generated net cash of $0.3 million, of which $1.7 million related to the exercise of stock options and issuance of shares under our ESPP, partially offset by $1.4 million related to payments made to government tax authorities for income tax withholding on RSU vesting, where shares are withheld by the Company.

We believe that based on our current market, revenue, expense and cash flow forecasts, our existing cash, cash equivalents and borrowing capacity will be sufficient to satisfy our anticipated cash requirements for the short and long-term. We currently have no credit facility but management believes we would be able to borrow on reasonable terms if needed.

On January 14, 2019 we announced that our Board of Directors authorized a one-year share repurchase program of up to $35 million of our common stock. These shares may be purchased in the open market or through privately negotiated transactions. We commenced repurchases of our stock in the second quarter, using $14.0 million in cash for this purpose. As of September 30, 2019, we had approximately $21.0 million remaining under the share repurchase program. See Part II, Item 2 of this report. We have no obligation to repurchase any additional shares under the authorization, and the timing, actual number and value of shares which are repurchased will depend on a number of factors, including the price of our common stock, general business and market conditions, and alternative investment opportunities. We may suspend or discontinue the repurchase program at any time.

### Commitments and Contingencies

Significant commitments and contingencies at September 30, 2019 are consistent with those discussed in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 16 to the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

## Market risk

As filed, 204 characters.

As of September 30, 2019, there have been no material changes to the quantitative information about market risk disclosed in Item 7A to our annual report on Form 10-K for the year ended December 31, 2018.

## Controls and procedures

As filed, 1,037 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report (the “Evaluation Date”). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the Evaluation Date, these disclosure controls and procedures are effective.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during the three months ended September 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 174 characters.

As of September 30, 2019, there have been no material changes to the risk factors described in Item 1A to our annual report on Form 10-K for the year ended December 31, 2018.

Filed Nov 7, 2019.
Source: SEC EDGAR, the filing index for accession 0001558370-19-010306. Last ingested by Listed: Nov 13, 2026, 17:24 ET. No prices; not investment advice.
